Recent Investment Analysts’ Ratings Changes for BridgeBio Pharma (BBIO)

BridgeBio Pharma (NASDAQ: BBIO) has recently received a number of price target changes and ratings updates:

• 5/11/2026 – BridgeBio Pharma had its price target raised by HC Wainwright from $100.00 to $110.00. They now have a “buy” rating on the stock.
• 4/29/2026 – BridgeBio Pharma had its price target raised by Truist Financial Corporation from $95.00 to $102.00. They now have a “buy” rating on the stock.
• 4/28/2026 – BridgeBio Pharma had its “outperform” rating reaffirmed by Mizuho. They now have a $106.00 price target on the stock.
• 4/27/2026 – BridgeBio Pharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
• 4/9/2026 – BridgeBio Pharma is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $100.00 price target on the stock.
• 4/8/2026 – BridgeBio Pharma was upgraded by Royal Bank Of Canada to “moderate buy”.
• 3/18/2026 – BridgeBio Pharma had its price target raised by Mizuho from $91.00 to $106.00. They now have an “outperform” rating on the stock.

Insiders Place Their Bets

In other news, Director Andrea Ellis sold 64,921 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total value of $4,211,425.27. Following the sale, the director directly owned 18,589 shares of the company’s stock, valued at approximately $1,205,868.43. The trade was a 77.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $67.90, for a total transaction of $2,716,000.00. Following the completion of the transaction, the chief executive officer owned 575,686 shares of the company’s stock, valued at $39,089,079.40. This trade represents a 6.50% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 239,084 shares of company stock worth $16,615,979. Insiders own 14.23% of the company’s stock.

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.